<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Oxygen affinity of <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, erythrocyte <z:chebi fb="0" ids="19324">2,3-diphosphoglycerate</z:chebi> (DPG) and <z:chebi fb="3" ids="15422">adenosine triphosphate</z:chebi> (ATP) concentrations were compared before and after oral administration of vinpocetine (TCV-3B) (15 mg/d), a primarily vasodilating agent, for three weeks in eight patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> of the Biswanger type which is characterized by diffuse myelin <z:hpo ids='HP_0000980'>pallor</z:hpo> and multiple lacunes in the cerebral white matter </plain></SENT>
<SENT sid="1" pm="."><plain>After vinpocetine administration, oxygen affinity of <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (P50) was significantly increased (26.5 +/- 0.55 to 27.6 +/- 0.62 mmHg; mean and standard deviation, p less than 0.05), red blood cell (RBC) ATP concentrations were significantly increased (846 +/- 168 to 1,158 +/- 130 mumol/l RBC, p less than 0.05), while DPG concentrations were unaltered (4.46 +/- 0.48 to 4.59 +/- 0.57 mmol/l RBC) </plain></SENT>
<SENT sid="2" pm="."><plain>There was a significant positive correlation between the increase of P50 and the increase of erythrocyte ATP concentrations (r = 0.67, p less than 0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>The effect of vinpocetine of enhancing oxygen release of <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> may offer an additional benefit to its primary vasodilating action in the treatment of vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> of the <z:e sem="disease" ids="C0270786" disease_type="Disease or Syndrome" abbrv="">Binswanger</z:e> type due to <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>